Onward Medical N.V. (ONWD.BR)
| Previous close | 4.8500 |
| Open | 4.9800 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 4.8100 - 5.0000 |
| 52-week range | 1.8500 - 6.5800 |
| Volume | |
| Avg. volume | 141,988 |
| Market cap | 175.222M |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.90 |
GlobeNewswireONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide rapid access to US Veterans Health Administration Continued to pioneer brain-computer interface therapies for SCI EINDHOVEN, The Netherlands, April 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore
- GlobeNewswire
ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast
EINDHOVEN, the Netherlands, April 11, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will publish Full Year 2023 Financial Results and host a webcast to discuss business highlights. The webcast will be held on April 25, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Ma
- GlobeNewswire
Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00
EINDHOVEN, the Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price of EUR 5.00 on April 8, 2024. Th
